The US economy is sending mixed signals, and it's hard to predict what's going to happen next. There are so many conflicting economic signals and contradictory data:
• The stock market signals optimism but bond markets are predicting a recession
• Manufacturing surveys are showing trouble but service sector measures are healthy, an odd imbalance.
• Even GDP and income measures disagree on economic activity.
• Housing data is m
A commonly followed measure of consumer confidence in the US economy just increased to the highest level since September 2021.
The first July reading of the University of Michigan Consumer Sentiment Index showed a reading of 72.6 on Friday. The print came in significantly higher than the 65.5 economists had expected and reflected a 13% increase from the month prior. That marks the fastest pace since December 2005, when the economy was recovering from Hurr
Amazon $AMZN Prime Day broke its sales records and achieved its highest sales in the company's history, with shoppers spending $12.7 billion on over 375 million items over the two-day event.
Read more:
Subramanian noted the S&P has returned 19% on average in the 12 months immediately following a 20% rally from a bottom; this would send the S&P to an all-time high of about 5,100.
There's more upside left in stocks after a new bull market started on Thursday, according to Bank of America.
"After crossing the +20% mark from the bottom, the S&P 500 continued to rise over the next 12 months 92% of the time," BofA said.
Nvidia $NVDA has invested $50 million in Recursion Pharmaceuticals $RXRX, an AI drug discovery platform, which has sent its stock up by 78%.
AI drug discovery has quickly become one of the hottest markets for investment in the startup sector. AI is transforming how new drugs are discovered, enabling faster and cheaper development.
Morgan Stanley expects AI to help develop an additional 50 drugs with an extra $50B in sales in the next decade.
I recently bought Neurocrine Biosciences, Inc. (NASDAQ: $NBIX). As a disclosure, I consider this to be a highly speculative investment. Perform your own due diligence.
Snapshot for Neurocrine Biosciences, Inc.
Sector: Healthcare
Industry: System-Specific Biopharmaceuticals
Country: USA
Current Price: $96.03
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is
NVDA abcd pattern played out flawlessly yesterday. NFLX has the same pattern and today looks like breakout day. A lot of people think charting and these patterns are witch craft but they work people! Learn to trade them and you can make a lot of money. Good luck today.
I think there are way too many tools and too much information out there these day, and I have developed a habit of keeping a shortlist of useful tools and information channels that I'll use for research and market updates. Below is my list, and I am curious to find out what others are using.
[EDIT: removed reference to a substack from the original post]
Tools
Tradingview (http://www.
In my foolishness, I was looking for some "easy" money and sold a CALL option on NVDA when it was still around $200.. The strike price is $500 and expiration on NOVEMBER, and I received a premium of $400 at the time. From there, I'm already at a loss of $3,600, and I can't take it anymore.
It's just a matter of time until it reaches $500, and then I'm completely lost. And to make matters worse, it's not even a covered call, (
JPMorgan Chase reported second-quarter earnings Friday that topped analysts’ expectations as the company benefited from higher interest rates and growing interest income.
- Earnings: $4.37 per share adjusted vs. $4 per share Refinitiv estimate
- Revenue: $42.4 billion vs. $38.96 billion estimate
Net income surged 67% to $14.5 billion, or $4.75 per share. When excluding the impact of its First Republic acquisition in early May — a